Product Information
BANZEL 40 MG/ML SUSPENSION is a brand product labeled by Eisai Inc., priced at $3.6487 per ML under NDC 62856058446. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Mar 3, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the rufinamide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
40 mg/mL
Manufacturer
Eisai Inc.NDC
62856058446
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RUFINAMIDEApproval Type
New Drug (NDA)
FDA Application
NDA201367FDA Approved
3/3/2011
TE Code
AB
On Market Since
3/3/2011
Price Statistics
The NADAC for BANZEL 40 MG/ML SUSPENSION has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 153.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.6487 per ML |
|---|---|
| All-time high | $3.7207 (Feb 15, 2023) |
| All-time low | $1.4378 (Nov 28, 2013) |
| 52-week high | $3.6567 |
| 52-week low | $3.6452 |
| Median price | $3.5103 |
| Average price | $3.1017 |
| Largest weekly change | +10.0% (Aug 20, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the rufinamide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eisai Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rufinamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BANZEL 40 MG/ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for BANZEL 40 MG/ML SUSPENSION, manufactured by Eisai Inc., is $3.6487 per ML (NDC 62856058446), effective Sep 30, 2026.
How has the price of BANZEL 40 MG/ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for BANZEL 40 MG/ML SUSPENSION has risen 153.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for BANZEL 40 MG/ML SUSPENSION?
Since Nov 28, 2013, the NADAC for BANZEL 40 MG/ML SUSPENSION has ranged from a low of $1.4378 (Nov 28, 2013) to a high of $3.7207 (Feb 15, 2023), with a median of $3.5103 per ML.
Are there cheaper alternatives to BANZEL 40 MG/ML SUSPENSION?
No other NADAC-published product currently shares the active ingredient and strength of BANZEL 40 MG/ML SUSPENSION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BANZEL 40 MG/ML SUSPENSION?
BANZEL 40 MG/ML SUSPENSION (NDC 62856058446) is labeled by Eisai Inc., and CMS classifies it as a brand product.